1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United Kingdom >
  5. Portage Biotech Acquires SalvaRx

M&A Deal Summary

Portage Biotech Acquires SalvaRx

On January 9, 2019, Portage Biotech acquired life science company SalvaRx

Acquisition Highlights
  • This is Portage Biotech’s 1st transaction in the Life Science sector.
  • This is Portage Biotech’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2019-01-09
Target SalvaRx
Sector Life Science
Buyer(s) Portage Biotech
Deal Type Add-on Acquisition

Target

SalvaRx

British Virgin Islands, United Kingdom
SalvaRx Ltd. is a drug development company focused on cancer immunotherapy and complementary areas of oncology.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Portage Biotech

Toronto, Ontario, Canada
Category Company
Sector Life Science
DESCRIPTION

Portage Biotech, Inc. is a pharmaceutical company that identifies, finances, and develops best-in-class or first-in-class early-to-mid stage products. Portage Biotech is based in Toronto, Ontario.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2019 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal